Clinical trial
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory…
NCT00004070 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004070 |
|---|---|
| Title | Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer |
| Official title | A Multi-Center, Open-Label, Multiple Administration, Rising Dose Study of the Safety, Tolerability, and Efficacy of IL-12 Gene Medicine in Patients With Unresectable or Recurrent/Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological |
| Interventions | IL-12 |
| Enrollment | 7 |
| Start date | Jul 1, 1999 |
| Primary completion | Nov 1, 2000 |
| Completion | Dec 1, 2000 |
| First posted | Jun 4, 2004 |
| Last update posted | Apr 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: